Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Tissue Regenix ( (GB:TRX) ) just unveiled an announcement.
Tissue Regenix Group PLC has announced a change in major holdings, as Lombard Odier Asset Management has increased its stake in the company to 13.01%, up from the previous 12.22%. This acquisition of voting rights by a significant asset manager may indicate confidence in the company’s strategic direction and growth potential, potentially impacting its market position and boosting investor interest.
More about Tissue Regenix
Tissue Regenix Group PLC is a company in the biotechnology industry, specializing in regenerative medicine. They focus on developing and commercializing technologies for tissue replacement and repair, concentrating on areas such as orthopedics, dental, and wound care.
YTD Price Performance: -2.50%
Average Trading Volume: 37,622
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £41.67M
See more data about TRX stock on TipRanks’ Stock Analysis page.
